SLC16A3 is a Prognostic Marker and Affects Immune Regulation in Bladder Cancer
View abstract on PubMed
Summary
This summary is machine-generated.High SLC16A3 expression in bladder cancer (BC) correlates with poor prognosis and influences immune infiltration. SLC16A3 may serve as a therapeutic target for BC detection and treatment.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Metabolism
Background
- Solute carrier family 16 member 3 (SLC16A3) overexpression is implicated in tumor development by regulating metabolism.
- Limited research exists on SLC16A3's role in bladder cancer (BC).
Purpose Of The Study
- To systematically analyze SLC16A3 expression and its clinical significance in bladder cancer.
- To investigate the relationship between SLC16A3, metabolism, m6A modification, and immune infiltration in BC.
Main Methods
- Utilized public BC datasets for expression analysis and correlation with clinical characteristics.
- Performed gene function, immunocorrelation, immunotherapy, and drug sensitivity analyses using R packages.
- Investigated SLC16A3 expression localization via single-cell sequencing and validated protein/RNA expression by RT-qPCR and IHC.
Main Results
- SLC16A3 was significantly overexpressed in BC cells, correlating with poor patient prognosis.
- Established a reliable prognostic model for BC patients based on SLC16A3 expression.
- Found significant associations between SLC16A3, m6A modification (ALKBH5), aerobic glycolysis genes, M2 macrophage infiltration, and immune checkpoints.
Conclusions
- Overexpression of SLC16A3 is an independent prognostic factor in bladder cancer.
- SLC16A3 may promote BC progression by influencing immune infiltration through metabolic and m6A methylation regulation.
- SLC16A3 presents a potential therapeutic target for BC detection and treatment.

